JPMorgan analyst Michael Weinstein downgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $150. The stock closed Friday down 81c to $139.72.

The analyst sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. He remains “fundamentally bullish” on the company, however.

Weinstein this morning upgraded both Abbott Laboratories (ABT) and Baxter International (BAX) to Overweight.